GlassScriptPhysician profile
Eric Jonathan Jenkie
NPI 1922448042
$7,051.11
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,078 · 2020: $584 · 2021: $571 · 2022: $1,751 · 2023: $2,022 · 2024: $44.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065 · Education: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.07 |
| Education | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,474.99 | 2019-2020 | |
| Ucb, INC. | $1,328.02 | 2019-2023 | Briviact, Nayzilam |
| Abbvie INC. | $448.38 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $357.92 | 2019-2023 | Ultomiris |
| Sk Life Science, INC. | $295.80 | 2021-2024 | |
| Lilly USA, LLC | $291.16 | 2019-2023 | Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $227.82 | 2022 | |
| Sunovion Pharmaceuticals INC. | $225.60 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $172.93 | 2020-2023 | Rytary |
| Csl Behring | $168.16 | 2020 | |
| Pfizer INC. | $153.78 | 2023 | |
| Neurelis, INC. | $148.76 | 2022-2024 | Valtoco |
| Avanir Pharmaceuticals, INC. | $134.28 | 2019-2020 | |
| Amgen INC. | $134.27 | 2020-2022 | |
| Allergan, INC. | $125.10 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Jenkie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.